Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 13

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 13
---
-Banting, Building 2, Suite 270, St-Laurent, Québec, Canada, and its
telephone number is (857) 412-7018.

The Company is a precision medicine oncology company focused
on the development of synthetic lethality-based therapies for patients with cancer. In January 2025, the Company announced a re-alignment of resources and a
re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-3467 and
RP-1664. On February 24, 2025, the Company approved a phased reorganization to reduce its workforce by approximately 75% by the fourth quarter of 2025, with remaining employees primarily focused on the
continued advancement of its Phase 1 clinical programs, RP-3467 and RP-1664. In May 2025, the Company announced the out-licensing
of its discovery platforms to DCx Biotherapeutics Corporation (“DCx”), and in July 2025, the Company announced an exclusive out-licensing agreement with Debiopharm International S.A.
(“Debiopharm”), for its lunresertib program. The Company continues to explore a full range of strategic alternatives, partnerships and sale opportunities across its portfolio to maximize shareholder value.

Additional information about the Company is contained in our Annual Report on Form 10-Kfor the fiscal year ended December 31, 2024, and in our subsequent Quarterly Reports on Form 10-Q,which are incorporated by reference herein and are available on the Company’s profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca. See “Where You Can Find More Information.”

XenoTherapeutics, Inc.

XenoTherapeutics, Inc. (the “Parent”) is a Massachusetts-based 501(c)(3) research foundation focused on
advancing xenotransplantation through scientific research, clinical development, and public education.

Xeno Acquisition Corp.

Xeno Acquisition Corp. (the “Purchaser”) is a wholly-owned subsidiary of Parent that will, among other things, acquire all
of the issued and outstanding Common Shares pursuant to the arrangement agreement (the “Agreement”), all as more particularly described in this Circular and Proxy Statement (the “Arrangement”).

XOMA Royalty Corporation

XOMA
Royalty Corporation (“XRC”) is a biotech royalty aggregator. XRC has a sizable portfolio of economic rights